Shionogi & Co., Ltd. (TYO:4507)

Market Cap	2.30T
Revenue (ttm)	440.50B
Net Income (ttm)	179.12B
Shares Out	850.78M
EPS (ttm)	210.53
PE Ratio	12.85
Forward PE	12.68
Dividend	66.00 (2.44%)
Ex-Dividend Date	Sep 29, 2025

Volume	2,138,300
Average Volume	2,299,785
Open	2,699.50
Previous Close	2,705.50
Day's Range	2,637.00 - 2,709.00
52-Week Range	2,028.50 - 2,724.00
Beta	0.12
RSI	73.45
Earnings Date	Jul 28, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,955
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4507

Financial Performance

In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.